This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering

Virogin Biotech


Virogin Biotech, founded in Vancouver Canada, is a clinical-stage immuno-oncology company, with a primary focus on innovative HSV-1 based oncolytic virotherapy (OV) and mRNA-based (including self-amplifying RNA/saRNA) therapeutics to elicit robust and durable anti-tumor immune response against solid tumors. Both the platforms exhibit a high degree of complementarity via a mechanism called heterologous prime-boost. Enhanced anti-tumor efficacy has been observed if OV and mRNA tumor vaccines were combined due to (1) modulation of immune-suppressive tumor microenvironment through release of immunological payloads carried by OV, and (2) antigen spread via direct tumor cell lysis triggered by OV infection, which functions like an in situ personalized tumor vaccine. Virogin strongly believe that this approach would break down the efficacy ceiling of tumor vaccines and elevate the modality to an unprecedented level. Each platform, mRNA or oncolytic virotherapy, possesses ‘plug-to-play' features to independently develop novel therapies against cancer & other indications. Our oncolytic HSV-1 platform has 2 clinical candidates, with our most advanced asset VG161 in Phase 2 clinical trial in the US and China. VG161 has obtained Orphan Drug Designation and Fast Track Designation from FDA demonstrating its potential for hard-to-treat solid tumors. The other clinical asset was based on our proprietary TTDR viral backbone showing both excellent safety profile and positive efficacy signals. In addition, Virogin has developed two self-amplifying RNA backbones, which dramatically improved IVT integrity for RNA longer than 8000 nucleotides with a yield of >5mg/mL. Candidates from our mRNA platform have also completed preclinical proof of concept with add-on features such as tumor-specific expression of target protein.